Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo

Horiuchi,Yutaka; Takagi,Akira; Uchida,Tetsuya; Akatsuka,Toshitaka

doi:10.3892/or.2015.4299

Targeting cryptic epitope with modified antigen coupled to the surface of liposomes induces strong antitumor CD8 T-cell immune responses in vivo

Authors:
- Yutaka Horiuchi
- Akira Takagi
- Tetsuya Uchida
- Toshitaka Akatsuka
View Affiliations

Affiliations: Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan
Published online on: September 21, 2015 https://doi.org/10.3892/or.2015.4299
Pages: 2827-2836
Copyright: © Horiuchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Active cancer immunotherapy, such as cancer vaccine, is based on the fundamental knowledge that tumor‑associated antigens (TAAs) are presented on MHC molecules for recognition by specific T cells. However, most TAAs are self-antigens and are also expressed on normal tissues, including the thymus. This fact raises the issue of the tolerance of the TAA‑specific T‑cell repertoire and consequently the inability to trigger a strong and efficient antitumor immune response. In the present study, we used antigens chemically coupled to the surface of liposomes to target telomerase reverse transcriptase (TERT), a widely expressed self/tumor antigen. Taking advantage of the high homology between mouse and human TERT, we investigated immunogenicity and antitumor efficiency of the liposomal TERT peptides in HLA-A*0201 transgenic HHD mice. Using the heteroclitical peptide-modifying approach with antigen‑coupled liposomes, we identified a novel cryptic epitope with low affinity for HLA*0201 molecules derived from TERT. The heteroclitical variant derived from this novel low affinity peptide exhibited strong affinity for HLA*0201 molecules. However, it induced only weak CD8 T‑cell immune responses in HHD mice when emulsified in IFA. By contrast, when coupled to the surface of the liposomes, it induced powerful CD8 T‑cell immune responses which cross-reacted against the original cryptic epitope. The induced CD8 T cells also recognized endogenously TERT‑expressing tumor cells and inhibited their growth in HHD mice. These data suggest that heteroclitical antigen derived from low affinity epitope of tumor antigens coupled to the surface of liposome may have a role as an effective cancer vaccine candidate.

View Figures

View References

1	Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, et al: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 5:677–685. 1999. View Article : Google Scholar : PubMed/NCBI
2	Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T and Rosenberg SA: Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA. 91:6458–6462. 1994. View Article : Google Scholar : PubMed/NCBI
3	Peek LJ, Middaugh CR and Berkland C: Nanotechnology in vaccine delivery. Adv Drug Deliv Rev. 60:915–928. 2008. View Article : Google Scholar : PubMed/NCBI
4	Taneichi M, Ishida H, Kajino K, Ogasawara K, Tanaka Y, Kasai M, Mori M, Nishida M, Yamamura H, Mizuguchi J, et al: Antigen chemically coupled to the surface of liposomes are cross-presented to CD8⁺ T cells and induce potent antitumor immunity. J Immunol. 177:2324–2330. 2006. View Article : Google Scholar : PubMed/NCBI
5	Takagi A, Matsui M, Ohno S, Duan H, Moriya O, Kobayashi N, Oda H, Mori M, Kobayashi A, Taneichi M, et al: Highly efficient antiviral CD8⁺ T-cell induction by peptides coupled to the surfaces of liposomes. Clin Vaccine Immunol. 16:1383–1392. 2009. View Article : Google Scholar : PubMed/NCBI
6	Taneichi M, Tanaka Y, kakiuchi T and uchida T: Liposome- coupled peptides induce long-lived memory CD8 T cells without CD4 T cells. PLoS One. 5:e150912010. View Article : Google Scholar
7	Vonderheide RH, Hahn WC, Schultze JL and Nadler LM: The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 10:673–679. 1999. View Article : Google Scholar : PubMed/NCBI
8	Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P and Zanetti M: Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA. 97:4796–4801. 2000. View Article : Google Scholar : PubMed/NCBI
9	Artandi SE and DePinho RA: Telomeres and telomerase in cancer. Carcinogenesis. 31:9–18. 2010. View Article : Google Scholar :
10	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
11	Liu JP, Chen W, Schwarer AP and Li H: Telomerase in cancer immunotherapy. Biochim Biophys Acta. 1805:35–42. 2010. View Article : Google Scholar
12	Arai J, Yasukawa M, Ohminami H, Kakimoto M, Hasegawa A and Fujita S: Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes. Blood. 97:2903–2907. 2001. View Article : Google Scholar : PubMed/NCBI
13	Warnock MG and Goodacre JA: Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases. Br J Rheumatol. 36:1144–1150. 1997. View Article : Google Scholar : PubMed/NCBI
14	Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O, Tourdot S, Chouaib S, Nadler LM, Lemonnier FA, et al: HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol. 168:5900–5906. 2002. View Article : Google Scholar : PubMed/NCBI
15	Gross DA, Graff-Dubois S, Opolon P, Cornet S, Alves P, Bennaceur-Griscelli A, Faure O, Guillaume P, Firat H, Chouaib S, et al: High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 113:425–433. 2004. View Article : Google Scholar : PubMed/NCBI
16	Tourdot S, Scardino A, Saloustrou E, Gross DA, Pascolo S, Cordopatis P, Lemonnier FA and Kosmatopoulos K: A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: Implication in the identification of cryptic tumor epitopes. Eur J Immunol. 30:3411–3421. 2000. View Article : Google Scholar : PubMed/NCBI
17	Thorn M, Wang M, Kløverpris H, Schmidt EGW, Fomsgaard A, Wenandy L, Berntsen A, Brunak S, Buus S and Claesson MH: Identification of a new hTERT-derived HLA-A^*0201 restricted, naturally processed CTL epitope. Cancer Immunol Immunother. 56:1755–1763. 2007. View Article : Google Scholar : PubMed/NCBI
18	Cole Dk, Edwards ES, Wynn KK, Clement M, Miles JJ, Ladell K, Ekeruche J, Gostick E, Adams KJ, Skowera A, et al: Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J Immunol. 185:2600–2610. 2010. View Article : Google Scholar : PubMed/NCBI
19	Pinolla-Ibarz J, May RJ, Koronitsvit T, Gomez M, Kappel B, Zakhaleva V, Zhang RH and Scheinberg DA: Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia. 20:2025–2033. 2006. View Article : Google Scholar
20	Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA and Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A^*0201-binding residues. J Immunol. 157:2539–2548. 1996.PubMed/NCBI
21	Kubo RT, Sette A, Grey HM, Appella E, Sakaguchi K, Zhu NZ, Arnott D, Sherman N, Shabanowitz J, Michel H, et al: Definition of specific peptide motifs for four major HLA-A alleles. J Immunol. 152:3913–3924. 1994.PubMed/NCBI
22	Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA and Pérarnau B: HLA-A2.1-restricted education and cytolytic activity of CD8(⁺) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med. 185:2043–2051. 1997. View Article : Google Scholar : PubMed/NCBI
23	Adotévi O, Mollier K, Neuveut C, Dosset M, Ravel P, Fridman WH, Tartour E, Charneau P, Wain-Hobson S and Langlade-Demoyen P: Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo. Blood. 115:3025–3032. 2010. View Article : Google Scholar : PubMed/NCBI
24	Takagi A, Kobayashi N, Taneichi M, Uchida T and Akatsuka T: Coupling to the surface of liposomes alters the immunogenicity of hepatitis C virus-derived peptides and confers sterile immunity. Biochem Biophys Res Commun. 430:183–189. 2013. View Article : Google Scholar
25	Kaech SM, Wherry EJ and Ahmed R: Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol. 2:251–262. 2002. View Article : Google Scholar : PubMed/NCBI
26	Greenberg RA, Allsopp RC, Chin L, Morin GB and DePinho RA: Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene. 16:1723–1730. 1998. View Article : Google Scholar : PubMed/NCBI
27	Forni G, Lollini PL, Musiani P and Colombo MP: Immunoprevention of cancer: Is the time ripe? Cancer Res. 60:2571–2575. 2000.PubMed/NCBI
28	Spurrell EL and Lockley M: Adaptive immunity in cancer immunology and therapeutics. E Cancer Med Sci. 8:4412014.
29	Blattman JN and Greenberg PD: Cancer immunotherapy: A treatment for the masses. Science. 305:200–205. 2004. View Article : Google Scholar : PubMed/NCBI
30	Mellman I, Coukos G and Dranoff G: Cancer immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
31	Patel KP and Vonderheide RH: Telomerase as a tumor-associated antigen for cancer immunotherapy. Cytotechnology. 45:91–99. 2004. View Article : Google Scholar
32	Beatty GL and Vonderheide RH: Telomerase as a universal tumor antigen for cancer vaccines. Expert Rev Vaccines. 7:881–887. 2008. View Article : Google Scholar : PubMed/NCBI
33	Liu K, Schoonmaker MM, Levine BL, June CH, Hodes RJ and Weng NP: Constitutive and regulated expression of telomerase reverse transcriptase (hTERT) in human lymphocytes. Proc Natl Acad Sci USA. 96:5147–5152. 1999. View Article : Google Scholar : PubMed/NCBI
34	Cibotti R, Kanellopoulos JM, Cabaniols JP, Halle-Panenko O, Kosmatopoulos K, Sercarz E and Kourilsky P: Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants. Proc Natl Acad Sci USA. 89:416–420. 1992. View Article : Google Scholar : PubMed/NCBI
35	Nanda NK and Sercarz EE: Induction of anti-self-immunity to cure cancer. Cell. 82:13–17. 1995. View Article : Google Scholar : PubMed/NCBI
36	Uram JN, Black CM, Flynn E, Huang L, Armstrong TD and Jaffee EM: Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol. 186:3847–3857. 2011. View Article : Google Scholar : PubMed/NCBI
37	Townsend ARM, Rothbard J, Gotch FM, Bahadur G, Wraith D and McMichael AJ: The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 44:959–968. 1986. View Article : Google Scholar : PubMed/NCBI
38	Tanaka Y, Taneichi M, Kasai M, Kakiuchi T and Uchida T: Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells. PLoS One. 5:e152252010. View Article : Google Scholar : PubMed/NCBI
39	Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI and Luiten RM: Vitiligo-like depigmentation in patients with stage III–IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis. J Clin Oncol. 33:773–781. 2015. View Article : Google Scholar : PubMed/NCBI
40	Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den Broek L, Fleuren GJ, Kenemans P, Kast WM and Melief CJ: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med. 186:695–704. 1997. View Article : Google Scholar : PubMed/NCBI
41	Harley CB: Telomerase and cancer therapeutics. Nat Rev Cancer. 8:167–179. 2008. View Article : Google Scholar : PubMed/NCBI
42	Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY and Weiner DB: Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity. Cancer Immunol Res. 1:179–189. 2013. View Article : Google Scholar
43	Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, Kentepozidis N, Mavroudis D and Georgoulias V: A phase II trial evaluating the clinical and immunologic response of HLA-A2(⁺) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 86:59–66. 2014. View Article : Google Scholar : PubMed/NCBI